Radix ranunculus temate saponins sensitizes ovarian cancer to Taxol via upregulation of miR‑let‑7b

You,Keli; Liu,Yuejun; Chen,Le; Ye,Haiyan; Lin,Wumei

doi:10.3892/etm.2022.11244

Radix ranunculus temate saponins sensitizes ovarian cancer to Taxol via upregulation of miR‑let‑7b

Authors:
- Keli You
- Yuejun Liu
- Le Chen
- Haiyan Ye
- Wumei Lin
View Affiliations

Affiliations: Department of Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, P.R. China, Department of Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, P.R. China
Published online on: March 4, 2022 https://doi.org/10.3892/etm.2022.11244
Article Number: 315
Copyright: © You et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A common cause of treatment failure in ovarian cancer is acquired drug resistance. Therefore, effective novel drugs against chemoresistance need to be developed. MicroRNAs (miRNAs or miRs) serve key regulatory roles in tumorigenesis and chemoresistance. The objective of the present study was to explore the role of miR‑let‑7b in ovarian cancer chemoresistance, and to develop novel strategy for the treatment of drug‑resistant ovarian cancer. For this purpose, reverse transcription‑quantitative PCR was performed to evaluate the expression level of miR‑let‑7b in fresh ovarian cancer tissues and cell lines. miR‑let‑7b mimic was transfected into ovarian cancer cell lines. Functional experiments, cell apoptosis and cell viability assays were carried out to identify the tumor‑suppressor function of miR‑let‑7b. The treatment effect of Radix ranunculus temate saponins (RRTS), one of the primary constituents extracted from the traditional Chinese medicine radix Ranunculi ternati, was identified in vitro and in vivo. The results revealed that miR‑let‑7b was downregulated significantly in chemoresistant ovarian cancer patients. miR‑let‑7b overexpression suppressed cell growth and invasion and enhanced sensitivity to Taxol of ovarian cancer cells. Furthermore, miR‑let‑7b levels in ovarian cancer tissue were inversely associated with collagen type III α1 chain (COL3A1) levels. COL3A1, a non‑fibrillar collagen associated with chemoresistance, was targeted by miR‑let‑7b. RRTS showed cytotoxic effects on ovarian cancer cells through inducing miR‑let‑7b expression and decreasing COL3A1 expression. In addition, RRTS sensitized ovarian cancer to Taxol both in vitro and in vivo. In conclusion, the present results revealed synergistic cytotoxicity of RRTS and Taxol on against ovarian cancer cells via upregulating expression of miR‑let‑7b. Combination of Taxol and RRTS may be a novel treatment strategy for patients with TR ovarian cancer.

View Figures

View References

1	Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis Primers. 2(16061)2016.PubMed/NCBI View Article : Google Scholar
2	Lheureux S, Gourley C, Vergote I and Oza AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.PubMed/NCBI View Article : Google Scholar
3	Gorodnova TV, Sokolenko AP, Kuligina E, Berlev IV and Imyanitov EN: Principles of clinical management of ovarian cancer. Chin Clin Oncol. 7(56)2018.PubMed/NCBI View Article : Google Scholar
4	Lee JM, Minasian L and Kohn EC: New strategies in ovarian cancer treatment. Cancer. 125 (Suppl 24):S4623–S4629. 2019.PubMed/NCBI View Article : Google Scholar
5	Christie EL and Bowtell DDL: Acquired chemotherapy resistance in ovarian cancer. Ann Oncol. 28 (Suppl 8):viii13–viii15. 2017.PubMed/NCBI View Article : Google Scholar
6	Freimund AE, Beach JA, Christie EL and Bowtell DDL: Mechanisms of drug resistance in high-grade serous ovarian cancer. Hematol Oncol Clin North Am. 32:983–996. 2018.PubMed/NCBI View Article : Google Scholar
7	Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey P, et al: Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521:489–494. 2015.PubMed/NCBI View Article : Google Scholar
8	Gebert LFR and MacRae IJ: Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 20:21–37. 2019.PubMed/NCBI View Article : Google Scholar
9	Dragomir MP, Knutsen E and Calin GA: Classical and noncanonical functions of miRNAs in cancers. Trends Genet: Oct 30, 2021 (Epub ahead of print).
10	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017.PubMed/NCBI View Article : Google Scholar
11	Goodall GJ and Wickramasinghe VO: RNA in cancer. Nat Rev Cancer. 21:22–36. 2021.PubMed/NCBI View Article : Google Scholar
12	Peng Y and Croce CM: The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 1(15004)2016.PubMed/NCBI View Article : Google Scholar
13	Ayers D and Vandesompele J: Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance. Genes (Basel). 8(95)2017.PubMed/NCBI View Article : Google Scholar
14	Fu TY, Chang CC, Lin CT, Lai CH, Peng SY, Ko YJ and Tang PC: Let-7b-mediated suppression of basigin expression and metastasis in mouse melanoma cells. Exp Cell Res. 317:445–451. 2011.PubMed/NCBI View Article : Google Scholar
15	Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M, Recker RR, Gatalica Z, Wang Z and Xiao GG: Let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol Med. 17:1233–1241. 2011.PubMed/NCBI View Article : Google Scholar
16	Xu H, Liu C, Zhang Y, Guo X, Liu Z, Luo Z, Chang Y, Liu S, Sun Z and Wang X: Let-7b-5p regulates proliferation and apoptosis in multiple myeloma by targeting IGF1R. Acta Biochim Biophys Sin (Shanghai). 46:965–972. 2014.PubMed/NCBI View Article : Google Scholar
17	Zhang W, Zhao W, Ge C, Li X, Yang X, Xiang Y and Sun Z: Decreased let-7b is associated with poor prognosis in glioma. Medicine (Baltimore). 98(e15784)2019.PubMed/NCBI View Article : Google Scholar
18	Chen F, Chen C, Yang S, Gong W, Wang Y, Cianflone K, Tang J and Wang DW: Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2. PLoS One. 7(e39197)2012.PubMed/NCBI View Article : Google Scholar
19	China Pharmacopoeia Committee: Pharmacopoeia of the People's Republic of China. China Chemical Industry Press, Beijing, pp223-224, 2005.
20	Tian JK, Sun F and Cheng YY: Chemical constituents from the roots of Ranunculus ternatus. J Asian Nat Prod Res. 8:35–39. 2006.PubMed/NCBI View Article : Google Scholar
21	Deng KZ, Xiong Y, Zhou B, Guan YM and Luo YM: Chemical constituents from the roots of Ranunculus ternatus and their inhibitory effects on Mycobacterium tuberculosis. Molecules. 18:11859–11865. 2013.PubMed/NCBI View Article : Google Scholar
22	Li ML, Gu HM, Hang HY, Jiang YL, Jiang J, Gu QN and WU WY: Radix ranunculus temate saponins induces apoptosis via the death receptor and mitochondrial pathways in SGC-7901 cells. Mol Cell Toxicol. 11:449–455. 2015.
23	Niu L, Zhou Y, Sun B, Hu J, Kong L and Duan S: Inhibitory effect of saponins and polysaccharides from Radix ranunculi ternati on human gastric cancer BGC823 cells. Afr J Tradit Complement Altern Med. 10:561–566. 2013.PubMed/NCBI View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
25	Di Sotto A, Irannejad H, Eufemi M, Mancinelli R, Abete L, Mammola CL, Altieri F, Mazzanti G and Di Giacomo S: Potentiation of Low-Dose Doxorubicin Cytotoxicity by Affecting P-Glycoprotein through Caryophyllane Sesquiterpenes in HepG2 Cells: An in vitro and in silico study. Int J Mol Sci. 21(633)2020.PubMed/NCBI View Article : Google Scholar
26	DI Giacomo S, DI Sotto A, Mazzanti G and Wink M: Chemosensitizing properties of β-caryophyllene and β-caryophyllene oxide in combination with doxorubicin in human cancer cells. Anticancer Res. 37:1191–1196. 2017.PubMed/NCBI View Article : Google Scholar
27	Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo JA, Varela MQ, Rubio MJ, Barretina-Ginesta MP and Gonzalez-Martin A: SEOM clinical guideline in ovarian cancer (2020). Clin Transl Oncol. 23:961–968. 2021.PubMed/NCBI View Article : Google Scholar
28	Marth C, Reimer D and Zeimet AG: Front-line therapy of advanced epithelial ovarian cancer: Standard treatment. Ann Oncol. 28 (Suppl 8):viii36–viii39. 2017.PubMed/NCBI View Article : Google Scholar
29	Weaver BA: How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25:2677–2681. 2014.PubMed/NCBI View Article : Google Scholar
30	Pokhriyal R, Hariprasad R, Kumar L and Hariprasad G: Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 11(1179299X19860815)2019.PubMed/NCBI View Article : Google Scholar
31	Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010.PubMed/NCBI View Article : Google Scholar
32	Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE and Gottesman MM: Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018.PubMed/NCBI View Article : Google Scholar
33	Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B and Gottesman MM: Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm. 8:2080–2088. 2011.PubMed/NCBI View Article : Google Scholar
34	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014.PubMed/NCBI View Article : Google Scholar
35	Lan H, Lu H, Wang X and Jin H: MicroRNAs as potential biomarkers in cancer: Opportunities and challenges. Biomed Res Int. 2015(125094)2015.PubMed/NCBI View Article : Google Scholar
36	Markou A, Liang Y and Lianidou E: Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clin Chem Lab Med. 49:1591–1603. 2011.PubMed/NCBI View Article : Google Scholar
37	Chen W, Cai F, Zhang B, Barekati Z and Zhong XY: The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: Potential biomarkers. Tumour Biol. 34:455–462. 2013.PubMed/NCBI View Article : Google Scholar
38	Shih KK, Qin LX, Tanner EJ, Zhou Q, Bisogna M, Dao F, Olvera N, Viale A, Barakat RR and Levine DA: A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol. 121:444–450. 2011.PubMed/NCBI View Article : Google Scholar
39	Chirshev E, Oberg KC, Ioffe YJ and Unternaehrer JJ: Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. Clin Trans Med. 8(24)2019.PubMed/NCBI View Article : Google Scholar
40	Xu S, Xu H, Wang W, Li S, Li H, Li T, Zhang W, Yu X and Liu L: The role of collagen in cancer: From bench to bedside. J Transl Med. 17(309)2019.PubMed/NCBI View Article : Google Scholar
41	Chauhan VP, Stylianopoulos T, Boucher Y and Jain RK: Delivery of molecular and nanoscale medicine to tumors: Transport barriers and strategies. Annu Rev Chem Biomol Eng. 2:281–298. 2011.PubMed/NCBI View Article : Google Scholar
42	Di Paolo A and Bocci G: Drug distribution in tumors: Mechanisms, role in drug resistance, and methods for modification. Curr Oncol Rep. 9:109–114. 2007.PubMed/NCBI View Article : Google Scholar
43	Ramanujan S, Pluen A, McKee TD, Brown EB, Boucher Y and Jain RK: Diffusion and convection in collagen gels: Implications for transport in the tumor interstitiumv. Biophys J. 83:1650–1660. 2002.PubMed/NCBI View Article : Google Scholar
44	Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y and Jain RK: Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 9:796–800. 2003.PubMed/NCBI View Article : Google Scholar
45	Cho A, Howell VM and Colvin EK: The extracellular matrix in epithelial ovarian cancer-A piece of a puzzle. Front Oncol. 5(245)2015.PubMed/NCBI View Article : Google Scholar
46	Januchowski R, Swierczewska M, Sterzynska K, Wojtowicz K, Nowicki M and Zabel M: Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines. J Cancer. 7:1295–1310. 2016.PubMed/NCBI View Article : Google Scholar
47	Engqvist H, Parris TZ, Kovacs A, Nemes S, Werner Rönnerman E, De Lara S, Biermann J, Sundfeldt K, Karlsson P and Helou K: Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas. BMC Cancer. 19(928)2019.PubMed/NCBI View Article : Google Scholar
48	Sun Q, Zhao H, Zhang C, Hu T, Wu J, Lin X, Luo D, Wang C, Meng L, Xi L, et al: Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers. Oncotarget. 8:42983–42996. 2017.PubMed/NCBI View Article : Google Scholar
49	Wang Q, She Y, Bi X, Zhao B, Ruan X and Tan Y: Dexmedetomidine protects PC12 cells from lidocaine-induced cytotoxicity through downregulation of COL3A1 mediated by miR-let-7b. DNA Cell Biol. 36:518–528. 2017.PubMed/NCBI View Article : Google Scholar
50	Yu DH, Ruan XL, Huang JY, Liu XP, Ma HL, Chen C, Hu WD and Li S: Analysis of the interaction network of Hub miRNAs-Hub genes, being involved in idiopathic pulmonary fibers and its emerging role in non-small cell lung cancer. Front Genet. 11(302)2020.PubMed/NCBI View Article : Google Scholar
51	Liu J, Luo C, Yin Z, Li P, Wang S, Chen J, He Q and Zhou J: Downregulation of let-7b promotes COL1A1 and COL1A2 expression in dermis and skin fibroblasts during heat wound repair. Mol Med Rep. 13:2683–2688. 2016.PubMed/NCBI View Article : Google Scholar